Now I have enough context to write a comprehensive earnings preview.# Albemarle Corporation (ALB) — Q2 2026 Earnings Preview Report Date: Wednesday, August 5, 2026 (after market close) | Call: Thursday, August 6, 8:00 AM ET
| Last close (8/4/26) | ~$120.85 |
| 52-week range (approx.) | $118 – $216 |
| YTD performance | Down sharply from April/May highs (~-44% off the April 16 peak of $215.62) |
| Consensus Q2 EPS | ~$3.12–$3.35 (adjusted) |
| Consensus Q2 Revenue | ~$1.59B (+~19% y/y) |
| Average analyst price target | ~$195–$220 (Buy/Moderate Buy consensus) |
The stock has been cut nearly in half since mid-May even as the company's own Q1 print was one of its best in years — that disconnect is the central tension investors need to resolve heading into Wednesday's report.
Albemarle's first-quarter 2026 results, reported May 6, were strong across the board. The company reported net sales of $1.4 billion, up 33% year-over-year, driven by higher volumes and pricing in Energy Storage (volumes +14%, price +51%) and Specialties (volumes +7%, price +2%), with adjusted EBITDA of $664 million, up 148%, and adjusted diluted EPS of $2.95 versus a loss a year earlier. Energy Storage EBITDA nearly tripled and Specialties EBITDA grew 30%. Management also raised full-year Specialties guidance (net sales to $1.3–$1.5B, EBITDA to $225–$275M) and executed aggressive balance-sheet work, paying down $1.3 billion of debt after closing the Eurecat and Ketjen divestitures, taking net debt/EBITDA to roughly 1.0x.
The stock initially responded well, rallying into mid-May. But since then, ALB has fallen from the ~$205–$210 area to roughly $118–$121 — a decline mirrored almost exactly by lithium peer SQM (down from ~$94 to ~$68 over the same window), while the broader market (S&P 500) and the materials sector ETF (XLB) were roughly flat to higher. That is the tell: this is a lithium-price story, not an Albemarle-specific operating problem.
The entire 2025–early 2026 lithium rally was largely a supply story. CATL's Jianxiawo mine in Jiangxi province — which accounted for roughly 8–10% of China's lithium carbonate output — lost its safety production permit in August 2025 and went offline, helping push spot lithium carbonate up sharply and giving Albemarle the pricing tailwind visible in its Q1 numbers (management referenced Q1 2026 average market pricing of ~$20/kg LCE versus a ~$10/kg average in 2025, with spot approaching $27/kg by the time of the May earnings call).
That supply squeeze began unwinding in late June: CATL received a new safety permit (valid June 29, 2026–February 27, 2028) and restarted Jianxiawo on June 29, while other idled capacity (Mineral Resources' Bald Hill, Core Lithium's Finniss) also came back online. Lithium carbonate futures fell roughly 10% over two sessions to a 10-week low in the days around the restart news, and by late July reports pointed to lithium prices hitting a five-month low on oversupply concerns, with global lithium production now projected to grow 26% year-over-year in 2026. That has been the proximate trigger for the sector-wide de-rating in ALB and SQM shares through July.
Sell-side has responded accordingly: Scotiabank cut its Q2 2026 EPS estimate for Albemarle to $4.01 from $4.24 in late July while maintaining an Outperform rating, and has full-year 2026/2027 EPS estimates of roughly $14.76/$15.56 — well above the shorter-run Street consensus figures circulating for the quarter itself (~$3.12–$3.35), reflecting how quickly numbers are moving. Notably, average price targets across the sell side (commonly cited in the $195–$220 range) still imply 60%+ upside from the current ~$120 share price — a gap that likely narrows via target cuts, a sharp snap-back in the stock, or both once Q2 numbers and fresh commentary are in hand.
On the Q1 call, management gave fairly specific sequential guidance that investors should hold the print up against:
Albemarle frames full-year guidance around three lithium price scenarios rather than a single point estimate:
| Scenario | Avg. lithium price | FY26 Net Sales | FY26 Adj. EBITDA |
|---|---|---|---|
| FY2025 avg. | ~$10/kg | $4.1–$4.3B | $0.9–$1.0B |
| Q1 2026 avg. | ~$20/kg | $5.7–$6.0B | $2.4–$2.6B |
| 2021–2025 avg. | ~$30/kg | $7.5–$7.8B | $4.2–$4.4B |
Q1's annualized run rate (adjusted EBITDA of $664M) tracked toward the upper end of the $20/kg scenario, aided by spot prices that briefly pushed toward $27/kg. With prices having since retraced meaningfully off those highs on the Jianxiawo restart and broader supply additions, the key question for Wednesday is whether management narrows, reaffirms, or shifts this scenario framework toward the lower end — and what commentary they offer on where spot pricing has actually landed relative to the $20 midpoint that underpinned the Q1 outlook.
Albemarle heads into Q2 earnings with a genuine disconnect: the underlying Q1 print showed the company firing on most cylinders (volume growth, cost discipline, balance sheet repair, raised Specialties guidance), yet the stock has been cut nearly in half since mid-May purely on the reversal of the lithium supply squeeze that drove pricing (and ALB shares) higher in the first place. SQM's near-identical decline confirms this is a commodity/sector re-rating rather than an ALB-specific issue.
The print itself will matter less for the immediate stock reaction than management's tone on where lithium pricing has actually settled post-Jianxiawo-restart, whether the $20/kg scenario framework still holds, and whether cost/productivity offsets are keeping pace with both Middle East disruption costs and a renewed pricing headwind. Given the wide gap between the current share price (~$120) and average Street price targets (~$195–220), this print and call commentary could be the catalyst that either triggers a wave of target cuts to catch down to the new pricing reality, or — if management can convincingly argue the sell-off has overshot the actual earnings impact — the start of a relief rally.